• Users Online: 257
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2017  |  Volume : 8  |  Issue : 4  |  Page : 127-134

Clinical use of vorapaxar as an emerging antithrombin agent: A literature review of current evidence


Department of Hematology Division, Internal Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia

Correspondence Address:
Dr. Farjah H Algahtani
King Saud University, Riyadh
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joah.joah_41_17

Rights and Permissions

In response to the high prevalence of atherothrombotic diseases and the residual risks left by the current antiplatelet therapies, the Food and Drug Administration approved the use of vorapaxar as a secondary prevention of cardiovascular events. Vorapaxar is a novel oral antiplatelet agent that antagonizes protease-activated receptor-1 and inhibits platelet activation without influencing coagulation parameters. In this review, we summarized findings of the main studies and the subanalyses from two pivotal phase III clinical trials of vorapaxar, as well as the results of the available observational studies to assist treatment decision-making of vorapaxar for clinicians. Evidence shows that vorapaxar treatment brings favorable results to patients with myocardial infraction history, peripheral arterial diseases, and acute coronary syndrome and those who underwent coronary artery bypass grafting surgery. Studies supported the efficacy of vorapaxar in treating incident coronary stent thrombosis, acute limb ischemia, and peripheral revascularization which outweighed the safety concern of bleeding. However, vorapaxar should not be administered to patients with prior stroke or transient ischemic attack due to excessive risks of bleeding. Future studies should focus on examining the long-term risks and benefits of vorapaxar on single cardiovascular outcomes and the optimal dosage of vorapaxar for different patient populations.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed762    
    Printed97    
    Emailed0    
    PDF Downloaded232    
    Comments [Add]    

Recommend this journal